Plain Language Summary

What is it about? This study examines the cost-effectiveness of 15 high-cost prescription drugs chosen by the Centers for Medicare and Medicaid Services for price negotiations in 2027. The topic is important as it addresses aligning drug prices with their actual value to patients and society. The researchers focused on understanding how these drug prices compare to the benefits they provide. The existing knowledge gap is the lack of comprehensive cost-effectiveness evaluations for these specific drugs under the new negotiation framework. The study proposes using cost-effectiveness analysis to ensure prices better reflect the value of the drugs. This research contributes to the broader understanding of how cost-effectiveness can guide drug pricing decisions.

How was the research conducted? The study is grounded in the use of cost-effectiveness analysis, a method that compares the cost of a drug to the health benefits it provides. Researchers applied this method by examining existing analyses from the Tufts Cost-Effectiveness Analysis Registry, focusing on 15 selected drugs. They reviewed each drug's base-case incremental cost-effectiveness ratios, which measure the additional cost per quality-adjusted life-year gained. The method employed was a data analysis of cost-effectiveness studies. The study analyzed drugs covered by Medicare, using a lifetime horizon for some analyses to capture long-term benefits. This method was chosen to provide a detailed understanding of how effective these drugs are compared to their costs.

What were the results? The main finding is that the cost-effectiveness of the drugs varied greatly, with incremental cost-effectiveness ratios ranging from $1800 to $640,000. Six drug indications had ratios below $50,000, while 10 exceeded $100,000. An additional finding was that studies based in the United States often reported higher cost-effectiveness ratios than those conducted elsewhere. There was significant difference in cost-effectiveness for drugs when considering industry-sponsored studies, which often showed more favorable results.

Why are the results important? For health technology assessment agencies, these results highlight the need for transparent and consistent use of cost-effectiveness analysis in drug pricing. These findings could lead to more informed and value-based decisions in clinical practice, ensuring that drug prices better reflect their benefits. Patients and healthcare providers could benefit from more equitable pricing that aligns with the actual value of the drugs. In the long term, these results could influence future policy developments, encouraging a more systematic approach to drug pricing decisions.

What are the strengths and weaknesses of this study? A major strength of the study is its comprehensive analysis of existing cost-effectiveness data, providing valuable insights for drug pricing negotiations. However, a limitation is the relatively small number of studies available for some drugs, leading to potential variability in results. Future research could expand this work by including more diverse methodologies and broader datasets to enhance the robustness of findings. This could further refine the integration of cost-effectiveness analysis in drug pricing strategies, benefiting patients, healthcare decision makers, and researchers.

Note: This content was created with assistance from artificial intelligence (AI) and has been reviewed and edited by ISPOR staff. For more information or for inquiries on ISPOR’s AI policy, click here or contact us at info@ispor.org.